Milestone Pharmaceuticals (MIST) Cash from Operations (2018 - 2026)

Milestone Pharmaceuticals (MIST) has reported Cash from Operations for 9 consecutive years, with -$22.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 80.76% year-over-year to -$22.7 million; the trailing twelve-month figure through Jun 2026 stood at -$61.3 million (down 51.79% YoY), and the FY2025 full-year result was -$49.0 million, down 70.0% from the prior year.
• Cash from Operations slipped to -$22.7 million in Q2 2026 per MIST's latest filing, from -$16.1 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$6.1 million in Q2 2024 and bottomed at -$22.7 million in Q2 2026.
• Historically, Cash from Operations has averaged -$12.0 million across 5 years, with a median of -$12.4 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations sank 1487.68% in 2022, then surged 42.7% in 2024.
• Over 5 years, Cash from Operations stood at -$12.9 million in 2022, then advanced by 23.84% to -$9.8 million in 2023, then jumped by 30.14% to -$6.8 million in 2024, then slumped by 86.69% to -$12.8 million in 2025, then plunged by 77.8% to -$22.7 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$22.7 million, -$16.1 million, and -$12.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.